Purpose Physicians require information on the comparative benefits and harms of medications for optimal treatment decisions. However, this type of data is limited, especially for pediatric patients. Objective Our aim was to use observational data to measure and compare medication utilization patterns in a pediatric patient population. Methods Using pharmacy claims data from a large, national-scale insurance program in the USA, we identified all patients with a diagnosis of epilepsy treated with a firstgeneration antiepileptic drug (carbamazepine, ethosuximide, phenobarbital, phenytoin, or valproate) or a second-generation antiepileptic drug [carbamazepine extended release (XR), gabapentin, lamotrigine, levetiracetam, oxcarbazepine, tiagabine, topiramate, valproate XR, or zonisamide]. Treatment periods were defined on the basis of prescription fill dates and medication days supplied. Medication use was measured for individual antiepileptic drugs and for firstgeneration and second-generation drugs as groups. Results There were 2527 patients (54 %) who initiated therapy with first-generation antiepileptics and 2139 patients (46 %) who initiated therapy with second-generation antiepileptics. First-and second-generation drugs had the same 1-year retention rates [26 % (95 % confidence interval (CI) 24-28) and 26 % (95 % CI 25-28), respectively], and 26 % of patients (95 % CI 25-28) and 29 % of patients (95 % CI 27-31) who started on a first-or second-generation antiepileptic medication, respectively, resumed treatment with the initial drug after discontinuation. Overall, 73 % of patients (95 % CI 71-74) were treated with only one antiepileptic drug, with similar rates for patients started on first-and second-generation drugs [71 % (95 % CI 69-73) versus 74 % (95 % CI 72-76)]. Conclusion Comparing drug utilization patterns in a pediatric population using observational data, we found similar rates of retention and therapeutic changes. These findings are consistent with the available comparative data and demonstrate an approach that could be extended to other drug classes and conditions in pediatric populations to examine drug effectiveness.
Introduction
Physicians frequently lack comparative data when choosing from the growing armamentarium of pharmaceuticals and, as a result, there is tremendous variation in treatment practice [1, 2] . The lack of comparative effectiveness data is particularly pronounced for pediatric patients, given the small number of drug trials conducted in children compared with adults [3] [4] [5] [6] [7] . Clinicians often show a preference for newer drugs, but, not infrequently, newer drugs are later found to be less effective or safe than previously existing options [8] [9] [10] . New drugs are generally approved on the basis of demonstrated superiority to placebo, and regulatory agencies-including the US Food and Drug Administration (FDA)-typically do not require comparison with existing agents [1, [11] [12] [13] . If there were information available to clinicians and patients on the advantages and disadvantages of a medication compared with others in the same class, they might be less likely to opt for the newer and more costly agent and might be better able to select the drug that would yield the greatest health benefits for a specific patient.
There are many barriers to conducting large, randomized, controlled drug trials in children, and sole reliance on these trials to increase comparative drug data in this population may not be feasible. Therefore, we sought to leverage observational data to compare drug effectiveness on the basis of drug utilization patterns, focusing here on first-and second-generation antiepileptic drugs in a pediatric patient population. For example, the length of time during which a patient continues therapy with a specific medicine may be reflective of the drug's efficacy, as well as its safety and tolerability, and these measures can be gleaned from prescription fill patterns in health insurance claims data.
Between 1994 and 2009, ten new antiepileptic agents were approved by the FDA and readily adopted by many clinicians [14] . However, there are limited data available describing how these newer, or second-generation, drugs compare with the older, first-generation agents [15] . Observational data on drug utilization may provide the opportunity to compare the effectiveness of different treatment options in large patient populations over extended periods and augment data generated in controlled trials. The aim of this study was to use observational data to measure and compare medication utilization in a pediatric patient population treated with antiepileptic drugs.
Methods

Data Source and Patient Population
The study population was 1,604,580 children between 0 and 18 years of age enrolled in a private, national-scale insurance program in the USA. Members enrolled in this plan shared a common employer, were located throughout the USA, and were fully insured. Insurance claims for the program were available from January 1, 1999, through December 31, 2006 , and included demographic data, information on medical encounters, and pharmacy prescription claims data. Prescription data consisted of National Drug Codes, date of prescription fill, and number of days supplied. Data on specific dosing regimens were not available. All patient information were de-identified. The Committee on Clinical Investigation at Boston Children's Hospital deemed that the study did not represent human subjects research and granted a waiver of informed consent.
Patients were included in the study if they were enrolled in the insurance program for at least 120 days without filling a prescription for an antiepileptic drug, had at least one medical encounter associated with a diagnosis of epilepsy or seizures (as defined in the International Classification of Diseases, Ninth Review, codes 345.xx, 779.0, 780.3x), and initiated antiepileptic therapy with a single antiepileptic medication [16] [17] [18] . We considered diagnoses associated with both outpatient and inpatient visits. For patients treated with a specific antiepileptic drug for 30 days or fewer with no subsequent prescriptions for the same drug within 12 months of the initial treatment, we used the second antiepileptic drug (whenever a second one was prescribed) as the index drug for analysis. This was done in order to avoid analyzing drug utilization for medications used on a temporary basis-for example, while the definitive medication was being titrated to the full dose. However, since this might also have led to the exclusion of patients who discontinued treatment because of safety or efficacy concerns within the first 30 days of treatment, we performed a sensitivity analysis in which patients treated with a medication for 30 days or fewer were included. The results were very similar to those of the main analysis in terms of comparative utilization patterns between first-and second-generation medications (see ''Appendix''). Patients with less than 1 year of continuous insurance coverage after initiation of the index drug were dropped from further analysis.
Definition of Antiepileptic Drugs
Antiepileptic drugs were identified on the basis of the Multum Drug Classification and included all medications listed in the ''anticonvulsants'' category [19] . We excluded acetazolamide, magnesium sulfate, clonazepam, diazepam, and lorazepam for the purposes of this study, since these are not considered primarily anticonvulsant agents. Ethotoin was also excluded because no patient in the study cohort was treated with this agent. First-generation drugs were those approved by the FDA pre-1993, and secondgeneration drugs were those approved post-1993 [20] .
Definition of Medication Treatment Periods
Medication treatment periods were defined as beginning on the day when a prescription was filled and extending for the total number of medication days supplied. Gaps in medication treatment were defined as the total number of continuous days without medication supply [16] . Gaps between prescriptions lasting 30 days or fewer were considered the result of poor medication adherence, and the period was analyzed as a continuous treatment period [16, [21] [22] [23] . This was done for consecutive prescriptions for the same drug, as well as for consecutive prescriptions for different antiepileptic agents. In these cases, the start date of the second prescription was considered the end date of the first prescription. Treatment gaps of 31 days or greater were defined as separate treatment periods.
Similarly, overlaps in treatment periods were not considered periods of combination therapy if they lasted 30 days or fewer. The treatment end date for the first drug was defined as the date on which the second agent was started. This was done for consecutive prescriptions of the same agent, as well as for consecutive prescriptions of different antiepileptic drugs. Periods of combination drug treatment were defined as periods lasting longer than 30 days during which the subject was treated with more than one antiepileptic medication.
Drug Comparisons
We compared medication usage, focusing on medication retention (continuation of treatment after medication start) and therapeutic changes during the first year following treatment initiation. We examined five measures of medication retention: (1) continuous treatment: days of continuous treatment with the index drug before any change in the antiepileptic drug regimen (including discontinuation of the index drug or addition of one or more antiepileptic drugs); (2) continuous treatment including polytherapy: days of continuous treatment with the index drug, including days of treatment with one or more other antiepileptic drugs; (3) proportion of treatment days with the index drug: proportion of total treatment days over the course of the study period during which patients were treated with the index drug; (4) 1-year retention: rate of index drug retention 1 year after initiation without any gaps in treatment or addition of other drugs; and (5) treatment resumption: proportion of patients who resumed treatment with the index drug after it had been discontinued.
Four measures described patterns of therapeutic changes following treatment initiation: (1) proportion of monotherapy: the proportion of patients treated with only the index drug throughout the study period; (2) proportion of polytherapy: the proportion of patients who required addition of a second antiepileptic drug concurrently with the index drug during the first treatment period; (3) number of antiepileptic drugs: the total number of anticonvulsants prescribed throughout the study period; and (4) number of therapeutic adjustments: the number of changes in the treatment regimen (including discontinuing, adding, and restarting an antiepileptic drug) throughout the study period.
Statistical Analysis
Medication use was measured for individual antiepileptic drugs and for first-generation and second-generation drugs as groups. Means and proportions were calculated with 95 % confidence intervals (CIs). Kaplan-Meier survival analyses were used to calculate retention rates at 1 year, and log-rank tests were performed to compare the retention curves. Post hoc analyses used the Sidak adjustment for multiple comparisons. All data were analyzed with SAS statistical software (version 9.3; SAS Institute Inc., Cary, NC, USA) [24] .
Results
Study Population
We identified 10,083 patients 0 to 18 years of age who had a medical encounter associated with the diagnosis of epilepsy or seizure and were treated with an antiepileptic agent. Of these, 6033 had a 120-day period without prescriptions for an antiepileptic drug and 6158 initiated treatment with a single agent. Of these, 879 patients were excluded because they were not continuously enrolled for 1 year after the initiation of the index drug. Another 478 patients were excluded because they were treated with an antiepileptic drug for 30 days or fewer without a second antiepileptic drug prescription. Five of the 19 antiepileptic drugs identified in the data set were dropped because few patients initiated treatment with them (felbamate N = 2, mephobarbital N = 2, methsuximide N = 1, pregabalin N = 1, and primidone N = 4). The final study cohort consisted of 4666 patients.
In our study sample, 2527 patients (54 %) initiated therapy with first-generation antiepileptic drugs and 2139 (46 %) initiated therapy with second-generation drugs ( Table 1) . The characteristics of patients initiating therapy with first-and second-generation drugs were slightly different, with patients initiating therapy with first-generation drugs being slightly younger and more likely to be male. Patients in the two groups had similar numbers of medical encounters, though patients initiating therapy with firstgeneration drugs had a slightly smaller mean number of total drug prescriptions.
Medication Use
The most frequently prescribed antiepileptic drugs at treatment initiation were valproate (N = 1158) and carbamazepine (N = 724) among the first-generation drugs, and oxcarbazepine (N = 601) and topiramate (N = 338) among the second-generation drugs ( Table 2 ). The same relative distribution held over the course of the first year of treatment, with valproate (N = 1439) and carbamazepine (N = 867) being the most frequently prescribed first-generation drugs, and oxcarbazepine (N = 780) and topiramate (N = 568) being the most commonly used secondgeneration drugs.
Medication Retention
Measures of medication retention showed very similar utilization patterns for first-and second-generation drugs during the first year of treatment (Table 3 Figs. 1 and 2 . When analyzed by category, there was no difference in mean survival rates for first-versus second-generation drugs (P = 0.87). However, within category, individual drugs did differ. For first-generation drugs, phenytoin had a lower survival rate than any of the other drugs (carbamazepine and ethosuximide P \ 0.001, valproate P = 0.007, phenobarbital P = 0.017). Carbamazepine also had a greater survival rate than phenobarbital (P = 0.003) and ethosuximide (P = 0.041). Among the second-generation drugs, oxcarbazepine had a greater survival rate than zonisamide, valproate extended release (XR), topiramate, gabapentin, tiagabine (P \ 0.001 for all), and levetiracetam (P = 0.027). Lamotrigine had a greater survival rate than topiramate (P \ 0.001) and gabapentin (P = 0.005). Carbamazepine XR had longer retention than gabapentin (P = 0.048) and topiramate (P = 0.004). Finally, topiramate had longer retention than tiagabine (P = 0.006) but shorter retention than levetiracetam (P = 0.008) and zonisamide (P = 0.011). 
Medication Changes
As shown in The sums of the patient numbers for first-and second-generation drugs add up to[100 % because some patients received treatment with drugs in both groups during the first year of treatment. Similarly, some patients were treated with more than one drug from either of the two drug groups c Phenobarbital has never been officially evaluated and approved by the US FDA, and the listed indication represents typical clinical use
Discussion
Comparing drug use in a pediatric population, using observational data, we found that first-and second-generation antiepileptic medications had very similar utilization patterns in terms of medication retention and therapeutic changes. In particular, patients initiating first-time therapy with a drug in either group had similar lengths of continuous treatment, rates of treatment resumption, 1-year retention rates, and rates of remaining on monotherapy with the index drug. We demonstrate the use of pharmacy claims data for investigation of drug prescription and utilization patterns, and our findings provide additional information to complement prior studies showing that the two drug classes are similar in terms of effectiveness [15, [25] [26] [27] [28] . This approach may be especially useful in augmenting information on drug utilization in pediatric populations, given the low rate of clinical trial research that has been performed in children compared with adults [3, 5, 29] . A number of reports have highlighted the paucity of evidence derived from clinical trials in children and have also identified alarming deficiencies in the quality of pediatric studies [6, 7, 30] . As a result, physicians frequently lack pediatric-specific data to guide clinical care around pharmacotherapy and are forced to extrapolate data from adult studies [31, 32] . Observational data on the clinical management and outcome of children treated with specific medications could be leveraged to fill in the gaps and complement data derived from controlled trials [33, 34] .
With the widespread and continuing adoption of electronic medical records, investigators have access to increasing volumes of high-quality observational data on clinical care. These data allow for retrospective or prospective examination of clinical data collected during routine clinical practice. Traditional randomized, controlled studies measure the efficacy of a treatment by using highly controlled experimental environments, volunteer Fig. 1 Kaplan-Meier survival analysis for first-and second-generation antiepileptic drugs by patients during the first year of treatment. There was no difference in the survival rates for first-and secondgeneration drugs (P = 0.87) CI confidence interval, XR extended release patients, atypical physicians and healthcare settings, and protocolized care [17, [35] [36] [37] [38] . The generalizability of their findings to clinical practice ultimately depends on how closely the trial protocols resemble real-world patient populations and treatment settings. Observational data, by contrast, are more likely to depict diverse patient populations and routine clinical care, and are a better measure of a treatment's effectiveness and of patients' behaviors in standard practice [39, 40] . Other advantages of observational data include the ability to study large patient populations, rare diseases, multiple treatment paradigms simultaneously, and extended treatment periods [40, 41] . This can be done at fairly low cost and high speed, compared with clinical trials [36] . However, careful consideration must be given to controlling for confounding, since the patient populations are not randomized [36, 40, 41] . Additionally, observational data may not be suitable for assessment of drugs that are newly introduced to the market, as data on their routine clinical use will not yet be available [42] . Medication retention has multiple determinants, including a patient's willingness to continue a treatment, and is a composite measure of a drug's efficacy, tolerability, safety, and patient preferences [43] [44] [45] [46] . It represents a measure of a drug's overall performance in the real world or, in other words, its effectiveness. As such, medication retention is considered one of the most relevant measures of the overall performance of an antiepileptic drug [47] [48] [49] . While medication retention has historically been measured as the proportion of patients continuing therapy at a set time point following treatment initiation, examining more detailed components of drug retention, as we did here, may provide insights into specific aspects of a drug's performance. For example, we found similar proportions of patients resuming therapy after treatment discontinuation, indicating that the tolerability of the two drug groups are likely comparable. Prior studies have suggested that a drug's tolerability may have a greater impact in determining its long-term retention than its efficacy [43, 44, 50] .
Along the same lines, changes in therapeutic regimens may be reflective of a patient's experience with a drug, including its tolerability and safety, when used in combination with other agents [44] . Measuring changes in therapy provides additional detail to complement drug retention rates, focusing on a drug's performance once its tolerability and safety in monotherapy have been established or identifying drug combinations that may increase a drug's retention.
Measuring real-world use of medications provides the opportunity to measure the comparative effectiveness of specific agents within drug classes, as well as the different treatment modalities available for a given condition. This may be particularly useful for conditions in which clinicians lack high-quality comparative data for the available drugs and other treatments [51] [52] [53] . Many trials testing new drugs use placebo controls as opposed to active comparators and additionally may suffer from a suboptimal choice of comparators [12, 36] . For example, a comparator drug may be unsuitable because it does not reflect the current standard of care for a condition or because it is administered at an inappropriate dose [11] . Comparative metrics based on observational data allow investigators to evaluate a treatment of interest in relation to any number of other therapies and, furthermore, to incorporate patient Fig. 2 Kaplan-Meier survival analysis for individual antiepileptic drugs by patients during the first year of therapy. a Depicts the five first-generation antiepileptic drugs examined. Phenytoin had a significantly lower survival rate compared with all other drugs (carbamazepine and ethosuximide: P \ 0.001; valproate: P = 0.007; phenobarbital: P = 0.017). Carbamazepine had a greater survival rate than phenobarbital (P = 0.003) and ethosuximide (P = 0.041). b Depicts the nine second-generation drugs examined. Oxcarbazepine had a greater survival rate than zonisamide, valproate extended release (XR), topiramate, gabapentin, tiagabine (P \ 0.001 for all) and levetiracetam (P = 0.027). Lamotrigine had a greater survival rate than topiramate (P \ 0.001) and gabapentin (P = 0.005). Carbamazepine XR had longer retention than gabapentin (P = 0.048) and topiramate (P = 0.004). Finally, topiramate had longer retention than tiagabine (P = 0.006) but shorter retention than levetiracetam (P = 0.008) and zonisamide (P = 0.011) behaviors and the conditions of administration in realworld practice.
The limitations of this study are those inherent to the use of retrospective claims data. There may have been miscoding of information or missing information due to patients discontinuing coverage with the insurance program. However, we do not expect these factors to be related to the use of specific antiepileptic drugs, and it is unlikely that they would affect our results comparing patients taking different drugs. The data also did not include additional information on the specific types of seizures that were being treated or the rationale behind medication choices, which might have enabled more selective inclusion of medication treatments for analysis. Similarly, no outcomes data are available, precluding specific analysis of the effectiveness of the medications. Given the observational nature of the data, we cannot exclude potential confounding by indication, although close examination of the two treatment groups, using the data available to us, indicated that they were very similar in terms of demographics and disease severity, as measured by medical encounters and overall drug use. Finally, while we employed a national data set covering an average of 900,343 children annually (range 738,766-1,058,723), we cannot ascertain the generalizability of our findings to other patient populations.
Conclusion
Few clinical trials have compared first-and second-generation antiepileptic drugs in children, with the available data indicating that the two drug classes are similar in terms of efficacy and safety [15, [25] [26] [27] [28] . Here, we compare drug utilization patterns in an observational pharmacy claims data set and identify similar rates of medication retention and changes. This approach generates information that may be useful in conjunction with traditional trial evidence. The methodology could readily be leveraged to other drug classes and conditions, and may be particularly relevant to pediatric populations, given the limited data frequently available on medication utilization in children.
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